Table 2. Prioritized BRAF mutations selected for experimental testing.

We selected these mutants because they were prioritized by Resistor for at least one of the investigated inhibitors and were reported as patient mutations in either the COSMIC or cBioPortal databases. The numbers in the first four columns indicate the Resistor-predicted Pareto rank with melanoma mutational probabilities. The numbers in the last two columns indicate the number of patient samples containing the mutation reported in the respective database (access date 01/12/2022). Absence of a Pareto rank indicates Resistor predicted the mutant would remain sensitive to the drug.

Mutation	Vemurafenib	Dabrafenib	Encorafenib	PLX8394	COSMIC	cBioPortal
G466E	-	1	-	-	49	31
G466R	-	1	-	-	17	3
V471F	-	-	2	3	5	2
L505H	-	-	3	-	8	10
G593D	1	1	1	1	4	0